

HIV, Hepatitis and Overdose among Drug Users: The Health Department Role in an Effective Response

444 North Capitol Street NW - Room 333 Washington, DC

April 22-23, 2014

Meeting Goal:

To provide a venue for health department HIV and viral hepatitis staff to examine their efforts to reduce HIV and HCV transmission and overdose among persons who inject drugs, and to develop plans to expand their efforts through the framework of drug user health.

Tuesday, April 22

Welcome and Introductions 2:00 - 2:30

Julie Scofield, Executive Director National Alliance of State and Territorial AIDS Directors

2:30 - 3:30**Defining the Problem and Prioritizing a Response:** HIV, HCV, Drug Use and Overdose in the U.S.

Daniel Raymond, Policy Director Harm Reduction Coalition

Alessandra Ross, Injection Drug Use Specialist California Department of Public Health

3:30 - 5:00 **Modernizing Our Approach to Drug User Health**

Brief remarks on innovative approaches to reimagine and modernize the public health approach to drug user health followed by a facilitated discussion of opportunities in participating states. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD.

Rachel McLean, Viral Hepatitis Prevention Coordinator California Department of Health



Dave Kern, Manager, Infectious Disease Prevention Washington State Department of Health

Alisa Solberg, Director Point Defiance Aids Projects, Tacoma, Washington

Moderator: Natalie Cramer, Director, Prevention National Alliance of State and Territorial AIDS Directors

5:00 - 5:30 **Preview of Day Two**

Chris Taylor, Associate Director, Viral Hepatitis National Alliance of State and Territorial AIDS Directors

5:30 Adjourn

Wednesday, April 23

8:30 - 9:00 **Breakfast (Provided)**

9:00 - 10:30 2014 Federal Priorities to Address HIV/HCV/Overdose

Representatives from key federal agencies will discuss programmatic and policy priorities related to HIV, HCV and overdose prevention, followed by a facilitated discussion with meeting participants. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD and federal agencies.

Christine Kourtides, Senior Policy Advisor Office of National Drug Control Policy

Amy Lansky, Deputy Director Division of HIV/AIDS Prevention, CDC

Jon Zibbell, Health Scientist/Medical Anthropologist Division of Viral Hepatitis, CDC

Melinda Campopiano, Medical Officer Substance Abuse and Mental Health Services Administration

Moderator, Murray Penner, Deputy Executive Director National Alliance of State and Territorial AIDS Directors



10:30 - 12:00 Infectious Diseases and Injection Drug Use

A facilitated discussion of what is occurring in participating states related to HIV and HCV prevention among people who inject drugs. Participants are encouraged to discuss what is occurring in their jurisdiction, what programs they would like to create/scale up and challenges they are experiencing. Health departments with extensive experience addressing these needs will participate in the discussion and share their expertise. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD. The following topics will help quide the discussion:

- Syringe Services Programs
- Surveillance and Data
- Policies and Legislation
- Funding and Grantees
- Young People who Inject Drugs
- Increased awareness/action related to overdose
- New HCV Treatments

Facilitator: Stephen Jones, Consultant T. Stephen Jones Consulting


Lunch (Provided) 12:00 - 1:00

1:00 - 2:30**Overdose Prevention: The State Response**

A facilitated discussion of what is occurring in participating states related to overdose prevention among people who inject drugs. Participants are encouraged to discuss what is occurring in their jurisdiction, what programs they would like to create/scale up and challenges they are experiencing. Health departments with extensive experience addressing these needs will participate in the discussion and share their expertise. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD. The following topics will help quide the discussion:

- Infectious Disease Role
- Cross Program Collaboration
- Data and Trends
- Funding and Grantees
- Policies and Legislation
- Increased awareness/action related to overdose

Facilitator: Sharon Stancliff, Medical Director Harm Reduction Coalition



2:30 - 3:30 **Action Agenda Development**

Meeting participants will have time to identify projects to focus on related to drug user health over the next twelve months and what technical assistance they will need to be successful.

Natalie Cramer, Director, Prevention National Alliance of State and Territorial AIDS Directors

Chris Taylor, Associate Director, Viral Hepatitis National Alliance of State and Territorial AIDS Directors

3:30 - 4:00 **Sharing of Action Agenda – Technical Assistance Needs**

Natalie Cramer, Director, Prevention National Alliance of State and Territorial AIDS Directors

Chris Taylor, Associate Director, Viral Hepatitis National Alliance of State and Territorial AIDS Directors

4:00 - 4:30 **Next Steps**

Murray Penner, Deputy Executive Director National Alliance of State and Territorial AIDS Directors

4:30 **Adjourn**